Abstract
National summaries produced by the Centers for Disease Control (CDC) and Society for Assisted Reproductive Technology (SART) are instructive in highlighting ART use trends but lag the market by 2-years. Here we explore gonadotropin utilization metrics as a surrogate and more proximate marker to assess US ART utilization. Resultant forecasts may be valuable for anticipating demand and better ensuring availability of resources.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
